Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02771314 | Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC | unknown | Phase 2 | 48 | Hellenic Oncology Research GroupOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT03840408 | Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung Cancer | unknown | N/A | 1,753 | Shanghai 10th People's HospitalOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT02726568 | High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases | unknown | Phase 2 | 30 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 19, 2019 | clinicaltrials |
| NCT03300115 | Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC | unknown | Phase 2 | 222 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Feb 19, 2019 | clinicaltrials |
| NCT03838588 | The Tracking Molecular Evolution for NSCLC (T-MENC) Study | unknown | — | 200 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT03823807 | A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC | unknown | Phase 2 | 300 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 0 | Feb 1, 2019 | clinicaltrials |
| NCT03603262 | Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC | unknown | Phase 1 | 85 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT03162705 | Molecular Profiling in Small Cell Lung Cancer(MPSCLC) | unknown | — | 120 | Zhujiang HospitalOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT03811054 | The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 60 | Beijing Chest HospitalOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT02480634 | Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer | unknown | Phase 4 | 280 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Jan 16, 2019 | clinicaltrials |
| NCT03799094 | Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations | unknown | Phase 1 / Phase 2 | 150 | Clifford Hospital, Guangzhou, ChinaOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT03799601 | Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC(ALTER-L013) | unknown | Phase 4 | 45 | Tongji HospitalOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT03791151 | Pharmacogenetics in Non Small Cell Lung Cancer | unknown | — | 100 | Ain Shams UniversityOTHER | 1 | Jan 2, 2019 | clinicaltrials |
| NCT03565120 | Aggressive Thoracic Radiotherapy for Stage Ⅳ Non Small Cell Lung Cancer | unknown | N/A | 60 | yu gengshengOTHER | 1 | Dec 26, 2018 | clinicaltrials |
| NCT03780283 | Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC | unknown | Phase 2 | 30 | First Hospital of Shijiazhuang CityOTHER | 1 | Dec 21, 2018 | clinicaltrials |
| NCT03781869 | Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer | unknown | Phase 2 | 116 | Third Military Medical UniversityOTHER | 0 | Dec 20, 2018 | clinicaltrials |
| NCT03432156 | Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 68 | Beijing Friendship HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03776604 | PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving Chemotherapy | unknown | N/A | 61 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03771404 | NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized "Liquid Biopsy" | unknown | N/A | 50 | Hellenic Oncology Research GroupOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT03765775 | Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative | unknown | Phase 2 | 20 | First Hospital of Shijiazhuang CityOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT03732001 | A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC(ALTER-L024) | unknown | Phase 2 | 80 | China Medical University, ChinaOTHER | 1 | Nov 28, 2018 | clinicaltrials |
| NCT03754530 | Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation | unknown | Phase 2 | 162 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT03750916 | Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer(ACDFNSNSCLC) | unknown | Phase 2 | 46 | Qilu Hospital of Shandong UniversityOTHER | 0 | Nov 26, 2018 | clinicaltrials |
| NCT03517332 | Circulating Tumor DNA Exposure in Peripheral Blood | unknown | — | 10,000 | Quantgene Inc.INDUSTRY | 2 | Nov 20, 2018 | clinicaltrials |
| NCT03664843 | Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients | unknown | — | 120 | First Hospital of Shijiazhuang CityOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT03735264 | Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034）(ACDFNSCLC) | unknown | Phase 2 | 46 | The Affiliated Hospital of Qingdao UniversityOTHER | 0 | Nov 8, 2018 | clinicaltrials |
| NCT03732846 | Anlotinib in Treatment of Recurrent Small Cell Lung Cancer | unknown | Phase 2 | 43 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT03728374 | Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma | unknown | Phase 2 | 38 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Nov 2, 2018 | clinicaltrials |
| NCT03725423 | Apatinib for Advanced Lung Squmamous Carcinoma | unknown | Phase 4 | 50 | Xuzhou Central HospitalOTHER | 0 | Oct 31, 2018 | clinicaltrials |
| NCT01788332 | Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)(PIN) | unknown | Phase 2 | 70 | Lisette NixonOTHER_GOV | 1 | Oct 26, 2018 | clinicaltrials |
| NCT03709953 | Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma(Spark-AL003) | unknown | Phase 2 | 33 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT03710629 | A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver Genes | unknown | — | 750 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT03700333 | Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced NSNSCLC | unknown | Phase 3 | 120 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Oct 9, 2018 | clinicaltrials |
| NCT03692442 | Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform | unknown | — | 80 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT03680183 | Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV) | unknown | — | 300 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Sep 28, 2018 | clinicaltrials |
| NCT02811354 | Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA(PLASMA) | unknown | Phase 2 | 108 | National University Hospital, SingaporeOTHER | 5 | Sep 20, 2018 | clinicaltrials |
| NCT03671538 | Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin | unknown | N/A | 62 | Lingyu LuoOTHER | 0 | Sep 17, 2018 | clinicaltrials |
| NCT03672136 | Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients | unknown | Phase 2 | 25 | Shandong Cancer Hospital and InstituteOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03407300 | A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 2 | 80 | Haining Health-Coming Biotech Co., Ltd.OTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT01407822 | Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer(EMERGING) | unknown | Phase 2 / Phase 3 | 72 | Guangdong Association of Clinical TrialsOTHER | 1 | Sep 11, 2018 | clinicaltrials |
| NCT03108560 | Sublobar Resection Versus Lobectomy for cT1N0M0 Non-small-cell Lung Cancer | unknown | N/A | 600 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT03509779 | Pronostic and Predictive Value of EMT in Localized Lung Cancer(TWISTlung) | unknown | — | 1,000 | European Georges Pompidou HospitalOTHER | 1 | Sep 6, 2018 | clinicaltrials |
| NCT01669707 | Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 60 | Beijing Chest HospitalOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT03523234 | Neoadjuvant Therapy Combined With Radical Surgery for the Treatment of Small Cell Lung Cancer (SCLC) in II and IIIA Stage | unknown | N/A | 300 | Peng ZhangOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT03656393 | To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma(RCTACSCNSCLC) | unknown | Phase 3 | 48 | Shenzhen People's HospitalOTHER | 1 | Sep 4, 2018 | clinicaltrials |
| NCT03654027 | Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC | unknown | Phase 2 | 84 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 0 | Aug 31, 2018 | clinicaltrials |
| NCT03651219 | Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer | unknown | Phase 3 | 90 | Beijing Chest HospitalOTHER | 0 | Aug 29, 2018 | clinicaltrials |
| NCT02450656 | Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer(M14AFS) | unknown | Phase 1 / Phase 2 | 320 | The Netherlands Cancer InstituteOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT03636685 | Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC | unknown | Phase 1 / Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 17, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Feb 22, 2019source: clinicaltrials